Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study

Naval Daver, Hagop M. Kantarjian, Keyur P. Patel et al.|Cancer Discovery|2018

Cited by 570